Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + SRS in NSCLC brain metastases
NCT06702826Phase 2Recruiting
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in non-small cell lung cancer (NSCLC). Started Nov 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06702826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702826.